Hybrid antibody mediated veto of cytotoxic T lymphocyte responses
- PMID: 8642307
- PMCID: PMC2192550
- DOI: 10.1084/jem.183.5.1973
Hybrid antibody mediated veto of cytotoxic T lymphocyte responses
Abstract
Strategies are being sought that allow the induction of specific tolerance to allogeneic transplants without affecting other immune functions. The so-called veto effect has been described as one such technology where CD8+ cells suppress responses of class I MHC-restricted T-lymphocyte precursors to antigens expressed by those CD8+ veto cells. Yet, veto inhibition will not be able to provide complete tolerance to allogeneic grafts since it only operates on cell populations that express CD8. Other types of cells prevalent in most organs express different tissue-specific antigens that are recognized by alloreactive T-cells. Therefore, complete tolerance to an allogeneic transplant can only be achieved if all cellular components within the graft acquire the immune-inhibitory function. Here, we studied whether the veto effect could be exploited for this purpose nevertheless. We produced a hybrid antibody (HAb) combining a mAb specific for a class I MHC molecule with a soluble CD8 molecule. We found that this HAb specifically and effectively transferred veto inhibition to different stimulator cell populations. Thus, we have developed a strategy that promises to selectively and completely tolerize graft-specific CTLs without affecting normal immune responses.
Similar articles
-
Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them.J Immunol. 1984 Oct;133(4):1775-81. J Immunol. 1984. PMID: 6332132
-
Tolerance induction by veto CTLs in the TCR transgenic 2C mouse model. I. Relative reactivity of different veto cells.J Immunol. 2004 Dec 1;173(11):6654-9. doi: 10.4049/jimmunol.173.11.6654. J Immunol. 2004. PMID: 15557156
-
Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.J Immunol. 1988 Feb 1;140(3):723-9. J Immunol. 1988. PMID: 2448374
-
Veto suppression: the peripheral way of T cell tolerization.Exp Clin Immunogenet. 1993;10(4):179-88. Exp Clin Immunogenet. 1993. PMID: 7907886 Review.
-
Veto function in vitro and in vivo.Int Rev Immunol. 1989 May;4(2):175-91. doi: 10.3109/08830188909044780. Int Rev Immunol. 1989. PMID: 2485841 Review.
Cited by
-
Inhibition of cytotoxic alloreactivity by human allogeneic mononuclear cells: evidence for veto function of CD2+ cells.Immunology. 1998 May;94(1):101-8. doi: 10.1046/j.1365-2567.1998.00480.x. Immunology. 1998. PMID: 9708193 Free PMC article.
-
New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints.Immunol Res. 2003;27(2-3):565-74. doi: 10.1385/IR:27:2-3:565. Immunol Res. 2003. PMID: 12857999 Review.
-
Treatment of an autoimmune disease with "classical" T cell veto: a proposal.J Clin Immunol. 1999 Jul;19(4):195-202. doi: 10.1023/a:1020511928974. J Clin Immunol. 1999. PMID: 10471973 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials